主任醫(yī)師，博士生導師，教授
中國臨床腫瘤學會(CSCO)副理事長兼秘書長
CSCO黑色素瘤專家委員會主任委員
CSCO腎癌專家委員會副主任委員
CSCO免疫治療專委會副主任委員
CSCO尿路上皮癌專委會副主任委員
CSCO前列腺癌專委會副主任委員
Melanoma World Society (MWS) 副主席
長期從事黑色素瘤、腎癌、膀胱癌、前列腺癌等皮膚、泌尿生殖腫瘤的臨床和轉(zhuǎn)化醫(yī)學研究，對于個體化靶向治療和生物免疫靶向治療方面積累了豐富的臨床經(jīng)驗。重要成果發(fā)表于J
ClinOncol，Blood，Annals of Oncol, Nat Commun, ClinCan
Res等重要SCI期刊，累計影響因子500余分，累計引用次數(shù)超過2000次。其中4篇文章被引入美國NCCN黑色素瘤、腎癌和頭頸部腫瘤診治指南(全國個人排名并列4)，多次入選ASCO年會口頭報告。曾獲北京市科技進步獎二等獎，中國抗癌協(xié)會科技獎二等獎，中華醫(yī)學會科技獎三等獎等。
發(fā)表論文
1. Si L, Zhang X, Xu Z, Jiang Q, Bu L, Wang X, Mao L, Zhang W, Richie N, Guo
J. Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable
or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer.
2018 May 3;18(1):520. IF=3.288
2. Cui C, Zhou L, Lian B, Si L, Sheng X, Chi Z, Kong Y, Wang X, Tang B, Mao
L, Li S, Dai J, Yan X, Bai X, Guo J. Safety and Efficacy of Apatinib Combined
with Temozolomide in Advanced Melanoma Patients after Conventional Treatment
Failure. Transl Oncol. 2018 Oct;11(5):1155-1159. IF=3.071
3. Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL,
Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua
B, Han J, Ahmad Q, Motzer R. Safety of pazopanib and sunitinib in
treatment-naive patients with metastatic renal cell carcinoma: Asian versus
non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018 May
22;11(1):69. IF=7.333
4. Yu J, Wu X, Yan J, Yu H, Xu L, Chi Z, Sheng X, Si L, Cui C, Dai J, Ma M,
Xu T, Kong Y, Guo J. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for
the treatment of Chinese melanoma patients. J Hematol Oncol. 2018 Jan 3;11(1):1.
IF=7.333
5. Cui C, Lian B, Zhou L, Song X, Zhang X, Wu D, Chi Z, Si L, Sheng X, Kong
Y, Tang B, Mao L, Wang X, Li S, Dai J, Yan X, Bai X, Balch CM, Guo J.
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706
Mucosal Melanoma Patients. Ann Surg Oncol. 2018 Aug;25(8):2184-2192.
IF=3.857
6. Li S, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X,
Chi Z, Guo J. Outcomes and Predictive Factors of Isolated Limb Infusion for
Patients with In-transit Melanoma in China. Ann Surg Oncol. 2018
Apr;25(4):885-893. IF=3.857
7. Tang H, Kong Y, Si L, Cui C, Sheng X, Chi Z, Dai J, Yu S, Ma M, Wu X, Yu
J, Xu T, Yu H, Yan J, Guo J. Clinical significance of BRAFV600E mutation in
circulating tumor DNA in Chinese patients with melanoma. Oncol Lett. 2018
Feb;15(2):1839-1844. IF=1.664
8. Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, Cui C, Chi Z, Si L, Li S,
Mao L, Lian B, Tang B, Yan X, Wang X, Kong Y, Dai J, Bai X, Zhou L, Guo J.
Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in
metastatic renal collecting duct carcinoma: A prospective, multicentre,
single-arm, phase 2 study. Eur J Cancer. 2018 Sep;100:1-7. IF=7.191
9. Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J.
First-line axitinib versus sorafenib in Asian patients with metastatic renal
cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol.
2019 Jan;15(1):53-63. IF=2.279.
10. Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X,
Bai X, Zhou L, Kong Y, Dai J, Wang K, Tang X, Zhou H, Wu H, Feng H, Yao S,
Flaherty KT, Guo J. Axitinib in Combination With Toripalimab, a Humanized
Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in
Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. J Clin
Oncol. 2019 Nov 10;37(32):2987-2999.IF = 28.349。
11. Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z,
Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der
Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV,
Mukhopadhyay P, Dummer R, Levesque MP, J?nsson G, Wang X, Yeh I, Wu H, Joseph N,
Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si
L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome
landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Nat Commun. 2019 Jul 18;10(1):3163.IF = 11.878。
12. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yu J, Yin T, Cheng Z, Wu X,
Yu H, Dai J, Sheng X, Si L, Cui C, Bai X, Mao L, Lian B, Wang X, Yan X, Li S,
Zhou L, Flaherty KT, Guo J, Kong Y. Genetic Aberrations in the CDK4 Pathway Are
Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with
Non-Cutaneous Melanoma. Clin Cancer Res. 2019 Nov 1;25(21):6511-6523. IF =
8.911
13. Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang
X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S,
Chi Z, Guo J. Safety and clinical activity with an anti-PD-1 antibody JS001 in
advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019 Jan
14;12(1):7. IF =8.731
14. Yu S, Dai J, Ma M, Xu T, Kong Y, Cui C, Chi Z, Si L, Tang H, Yang L,
Sheng X, Guo J. RBCK1 promotes p53 degradation via ubiquitination in renal cell
carcinoma. Cell Death Dis. 2019 Mar 15;10(4):254. IF =5.959
15. Yu J, Wu X, Yan J, Yu J, Yin T, Dai J, Ma M, Xu T, Yu H, Xu L, Yang L,
Cheng Z, Chi Z, Sheng X, Si L, Cui C, Guo J, Kong Y. Potential Mutations in
Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. J Cancer.
2019 Jan 1;10(2):488-493. IF = 3.182
16. Cui C, Yan X, Liu S, Deitz AC, Si L, Chi Z, et al.. Real-world clinical
outcomes of anticancer treatments in patients with advanced melanoma in China:
retrospective, observational study. International Journal of Surgery: Oncology.
2019;4(6):e76. IF =3.158
17. Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Lou F, Mao L, Wang X, Wen X, Gu
Y, Zhu L, Lan S, Cai X, Diede SJ, Zhou Y, Ge J, Li J, Wu H, Guo J. A Phase Ib
Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced
or Metastatic Melanoma (KEYNOTE-151). Transl Oncol. 2019 Jun;12(6):828-835. IF
=3.138
18. Wang X, Kong Y, Chi Z, Sheng X, Cui C, Mao L, Lian B, Tang B, Yan X, Si
L, Guo J. Primary malignant melanoma of the esophagus: A retrospective analysis
of clinical features, management, and survival of 76 patients. Thorac Cancer.
2019 Apr;10(4):950-956. IF = 2.524
19. Yan J, Xu L, Yu J, Wu X, Dai J, Xu T, Yu H, Guo J, Kong Y. Prognostic
role of NRAS isoforms in Chinese melanoma patients. Melanoma Res. 2019
Jun;29(3):263-269. IF = 2.381
20. Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J.
First-line axitinib versus sorafenib in Asian patients with metastatic renal
cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol.
2019 Jan;15(1):53-63. IF = 2.279
21. Yan X, Sheng X, Chi Z, Si L, Cui C, Kong Y, Tang B, Mao L, Wang X, Lian
B, Li S, Bai X, Zhou L, Dai J, Yao H, Guo J. Randomized Phase II Study of
Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With
Previously Untreated Advanced Mucosal Melanoma. J Clin Oncol. 2021 Mar
10;39(8):881-889. IF = 44.544.
22. Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song
H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J. Safety, Efficacy, and Biomarker
Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the
POLARIS-01 Multicenter Phase II Trial. Clin Cancer Res. 2020 Aug
15;26(16):4250-4259. doi: 10.1158/1078-0432.CCR-19-3922. IF=10.107.
23. Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A,
Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J.
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients
with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer. 2020
Aug;135:31-38. IF=7.275
24. Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X,
Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J. Phase 1 trial of vorolanib
(CM082) in combination with everolimus in patients with advanced clear-cell
renal cell carcinoma. EBioMedicine. 2020 May;55:102755. IF=5.736
25. Yu J, Yu J, Wu X, Guo Q, Yin T, Cheng Z, Dai J, Kong Y, Guo J. The TERT
copy number gain is sensitive to telomerase inhibitors in human melanoma. Clin
Sci (Lond). 2020 Jan 31;134(2):193-205. IF=5.223
26. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X,
Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1
Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical
Studies. Front Oncol. 2020 Sep 29;10:546604. IF=4.848
27. Wang ZL, Mao LL, Zhou ZG, Si L, Zhu HT, Chen X, Zhou MJ, Sun YS, Guo J.
Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to
Immunotherapy in Patients With Metastatic Melanoma. Front Oncol. 2020 Aug
25;10:1524. IF=4.848
28. Dai J, Yang L, Xu T, Si L, Cui C, Sheng X, Chi Z, Mao L, Lian B, Tang B,
Bai X, Zhou L, Li S, Wang X, Yan X, Kong Y, Guo J. A Functional Synonymous
Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma. J
Cancer. 2020 Mar 4;11(10):2945-2956. IF=3.565
29. Wang X, Xu W, Chi Z, Si L, Sheng X, Kong Y, Zhou L, Mao L, Lian B, Tang
B, Yan X, Bai X, Cui C, Guo J. Chemotherapy combined with antiangiogenic drugs
as salvage therapy in advanced melanoma patients progressing on PD-1
immunotherapy. Transl Oncol. 2021 Jan;14(1):100949. IF=4.243
30. Tang B, Chi Z, Guo J. Toripalimab for the treatment of melanoma. Expert
Opin Biol Ther. 2020 Aug;20(8):863-869. IF=3.224
31. Sheng X, Jin J, He Z, Huang Y, Zhou A, Wang J, Ren X, Ye D, Zhang X, Qin
S, Zhou F, Wang B, Guo J. Pazopanib versus sunitinib in Chinese patients with
locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis
from the randomized, COMPARZ studies. BMC Cancer. 2020 Mar 14;20(1):219.
IF=3.15
32. Yu J, Xu L, Yan J, Yu J, Wu X, Dai J, Guo J, Kong Y. MUC4 isoforms
expression profiling and prognosis value in Chinese melanoma patients. Clin Exp
Med. 2020 May;20(2):299-311.IF=2.644
33. Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, Yang X, Wei X, Cohen J,
Lawrence D, Freedman C, Fadden R, Rubin K, Sharova T, Frederick D, Flaherty K,
Sullivan R, Guo J, Boland G. Radiological dynamics and SITC-defined resistance
types of advanced melanoma during anti-PD-1 monotherapy: an independent
single-blind observational study on an international cohort. J Immunother
Cancer. 2021 Feb;9(2):e002092. (IF=13.751)
34. Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G,
Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J.
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting
Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic
Urothelial Carcinoma. Clin Cancer Res. 2021 Jan 1;27(1):43-51.IF=10.107.
(IF=12.531)
35. Sheng X, Chen H, Hu B, Yao X, Liu Z, Yao X, Guo H, Hu Y, Ji Z, Luo H, Shi
B, Liu J, Wu J, Zhou F, He Z, Fan J, Wang W, Feng H, Yao S, Keegan P, Huang Y,
Guo J. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with
Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter
Phase II Trial POLARIS-03. Clin Cancer Res. 2022 Feb 1;28(3):489-497.
(IF=12.531)
36. Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B,
Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova
G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick
DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson
DB, Sullivan RJ, Boland GM. Early Use of High-Dose Glucocorticoid for the
Management of irAE Is Associated with Poorer Survival in Patients with Advanced
Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021 Nov
1;27(21):5993-6000. (IF=12.531)
37. Mao L, Dai J, Cao Y, Bai X, Sheng X, Chi Z, Cui C, Kong Y, Zhang Y, Wu L,
Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Qi Z, Si L, Guo J.
Palbociclib in advanced acral melanoma with genetic aberrations in the
cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 May;148:297-306.
IF=9.162
38. Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S,
Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X. Real-world
efficacy and safety of axitinib in combination with anti-programmed cell death-1
antibody for advanced mucosal melanoma. Eur J Cancer. 2021 Oct;156:83-92.
IF=9.162
39. Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal
Melanoma: Current Status and Future Directions. Front Immunol. 2021 Jun
4;12:680407. IF=7.561
40. Zhou L, Wang X, Chi Z, Sheng X, Kong Y, Mao L, Lian B, Tang B, Yan X, Bai
X, Li S, Guo J, Cui C, Si L. Association of NRAS Mutation With Clinical Outcomes
of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian
Clinical Trials. Front Immunol. 2021 Jul 5;12:691032. IF=7.561
41. Cui C, Xu C, Yang W, Chi Z, Sheng X, Si L, Xie Y, Yu J, Wang S, Yu R, Guo
J, Kong Y. Ratio of the interferon-γ signature to the immunosuppression
signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021
Feb 4;6(1):7. IF=8.617
42. Mao L, Ding Y, Bai X, Sheng X, Dai J, Chi Z, Cui C, Kong Y, Fan Y, Xu Y,
Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Guo J, Zhang X, Si L.
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant
Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term
Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Front Oncol. 2021 Aug
24;11:720044. IF=6.244
43. Bai X, Dai J, Li C, Cui C, Mao L, Wei X, Sheng X, Chi Z, Yan X, Tang B,
Lian B, Wang X, Zhou L, Li S, Kong Y, Qi Z, Xu H, Duan R, Guo J, Si L. Risk
Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc
Analyses of Pooled Data From Two Clinical Trials. Front Oncol. 2021 May
20;11:639085. IF=6.244
44. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X,
Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1
Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical
Studies. Front Oncol. 2020 Sep 29;10:546604. IF=6.244
| 在線咨詢 | 院長信箱 | 化驗單查詢 | 檢查報告查詢 |
